OVERVIEW
Reduce your trial risk and improve outcomes
Sponsors partnering with Clario gain access to expert solutions designed to enhance the accuracy, reliability, and success of psychiatric disorder clinical trials. Our comprehensive services are aimed at reducing risks and improving trial outcomes and include:
- eCOA training
- Placebo response mitigation
- Advanced cardiac and respiratory safety strategies
- Cutting-edge medical imaging
With global expertise and end-to-end support, we help sponsors navigate the complexities of psychiatric drug development while ensuring data integrity and regulatory compliance throughout the trial lifecycle.
SOLUTIONS AND EXPERTISE
Expert solutions for psychiatric disorder trials
Deliver precise and dependable data
Psychiatric drug studies face many data challenges, including errors or bias in clinical outcome assessments (COAs), and high placebo response.
We offer extensive training for COA raters and scientifically driven placebo mitigation strategies, so you collect robust, high-quality data for your candidate.
Measure valuable endpoints
Assessing psychiatric drugs is complex and benefits from a composite approach including COAs, imaging, and cardiac endpoints to characterize the disease, monitor changes, and determine the safety profile.
Learn how to take a holistic approach and better understand the performance of your drug. Watch our free on-demand webinar for more information.
Enhance trial outcomes with expert training
Patient recruitment and retention, caregiver participation, and overall ease of use are critical for a successful psychiatric clinical trial.
Use COAs designed for accessibility and usability, leverage our rater training program, and work with an experienced Phase I site that’s part of our certified network to quickly get your study started.
Watch the video to see how we train participants and caregivers for eCOAs.
Scientific and regulatory expertise
Collecting high quality data is only half the story. Our experts have supported over 800 psychiatric drug trials and 100 drug approvals.2
Take advantage of our experience to effectively design, execute, and report for these trials.
Decades of experience have taught us the pitfalls of psychiatric drug studies
Let’s work together to avoid them
We mitigate data quality risks across a range of endpoints, create trial experiences that promote patient recruitment and retention, and deliver end-to-end solutions to support your business goals.
Resources
Neuroscience Services
Clario certified sites
Benefits of Utilizing Early Precision QT and Artificial Intelligence-Powered Data Quality Assessments in Early Phase Trials Webinar Replay
References
- World Health Organization. Mental disorders. World Health Organization. Published 2022. https://www.who.int/news-room/fact-sheets/detail/mental-disorders
- Clario internal data through September 30, 2024
- Internal proprietary data